Physician profile
Julius Boateng
NPI 1093796559
$1,388.14
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,013 · 2020: $234 · 2021: $92.43 · 2022: $48.69.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $275.21 | 2019-2021 | |
| Novo Nordisk INC | $191.49 | 2019-2022 | |
| Astellas Pharma US INC | $187.46 | 2019-2021 | |
| Horizon Therapeutics Plc | $135.66 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $120.08 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $111.79 | 2019-2020 | |
| Pfizer INC. | $71.01 | 2019-2020 | |
| Ucb, INC. | $62.27 | 2019 | |
| Abbvie INC. | $43.74 | 2019 | |
| Allergan, INC. | $43.11 | 2019-2020 | |
| Glaxosmithkline, LLC. | $23.96 | 2020 | |
| Amarin Pharma, INC. | $23.01 | 2020 | |
| Sunovion Pharmaceuticals INC. | $19.87 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $18.29 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.62 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $15.82 | 2019 | |
| Merck Sharp & Dohme LLC | $14.75 | 2019 | |
| Sanofi Pasteur INC. | $14.00 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julius Boateng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.